Adaptimmune Therapeutics (Adaptimmune Therapeutics) EPS (Diluted) : $-0.47 (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Adaptimmune Therapeutics EPS (Diluted)?

Adaptimmune Therapeutics's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.18. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.47.

Adaptimmune Therapeutics's EPS (Basic) for the three months ended in Dec. 2023 was $-0.18. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.47.

Adaptimmune Therapeutics's EPS without NRI for the three months ended in Dec. 2023 was $-0.18. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.56.

During the past 3 years, the average EPS without NRIGrowth Rate was 11.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was 7.80% per year. During the past 10 years, the average EPS without NRI Growth Rate was -33.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 12 years, Adaptimmune Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 11.60% per year. The lowest was -272.20% per year. And the median was -1.75% per year.

Adaptimmune Therapeutics EPS (Diluted) Historical Data

The historical data trend for Adaptimmune Therapeutics's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adaptimmune Therapeutics EPS (Diluted) Chart

Adaptimmune Therapeutics Annual Data

Trend

Jun14

Jun15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Diluted)

Get a 7-Day Free Trial

-1.32

-0.90

-1.02

-0.54

Adaptimmune Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EPS (Diluted)	Get a 7-Day Free Trial															-0.18	0.01	-0.12	-0.18	-0.18

Competitive Comparison of Adaptimmune Therapeutics's EPS (Diluted)

For the Biotechnology subindustry, Adaptimmune Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adaptimmune Therapeutics's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adaptimmune Therapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Adaptimmune Therapeutics's PE Ratio falls into.

Adaptimmune Therapeutics EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Adaptimmune Therapeutics's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-113.871	-	0)	/	201.073
	=	-0.57

Adaptimmune Therapeutics's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-47.917	-	0)	/	227.398
	=	-0.21

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.47

Adaptimmune Therapeutics (NAS:ADAP) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Adaptimmune Therapeutics EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Adaptimmune Therapeutics's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Adaptimmune Therapeutics (Adaptimmune Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptimmune Therapeutics PLC (NAS:ADAP) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

473A:Germany

Address

60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY

Website

https://www.adaptimmune.com

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A10 T-cell therapy, non-small cell lung cancer, AFP SPEAR T-cell, MAGE-A4 SPEAR T-cell therapy and NY-ESO SPEAR T-cell for multiple cancer types.

Executives

Elliot Norry	officer: Chief Medical Officer	C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Bertrand William C Jr	officer: Chief Operating Officer	C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
John Lunger	officer: Chief Patient Supply Officer	C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Adrian Rawcliffe	officer: Chief Financial Officer	440 SOUTH BROAD STREET, UNIT 1906, PHILADELPHIA PA 19146
Kristen Hege	director	500 FORBES BLVD, SOUTH SAN FRANCISCO CA 94070
Garry E Menzel	director	C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT SUITE 210, SAN DIEGO CA 92121
Priti Hegde	director	TCR2 THERAPEUTICS INC., 100 BINNEY STREET, SUITE 710, CAMBRIDGE MA 02142
Andrew R Allen	director	2525 28TH STREET, SUITE 200, BOULDER CO 80301
Cintia Piccina	officer: Chief Commercial Officer	60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 X0 OX14 4R
Gavin Wood	officer: Chief Financial Officer	C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Joanna Elizabeth Brewer	officer: Chief Scientific Officer	60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Helena Katrina Tayton-martin	officer: Chief Operating Officer	C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
David M Mott	director	1119 ST. PAUL STREET, BALTIMORE MD 21202
Lawrence M Alleva	director	1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
James Noble	director, officer: Chief Executive Officer	C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX